Biotechnology, which is considered a key technology in the 21st century, plays an important role in progress and promotion of life science and health/medicinal science; furthermore, also it is expected to solve the various contemporary issues such as the problem of aging society, environment/food problem and energy problem. The PSS group has a corporate philosophy to contribute to human health and happiness as a "total-system integrator in bioindustry" and wishes to achieve mid- and long-term expansion and growth, and thus contribute to stakeholders including stock owners, business partners and employees.
The PSS group, as a venture in the bio-related industries, had experienced fluctuated business results for years, before we have finally established solid profitability, largely due to the large R&D investment. Therefore, PSS hasn't had any key performance indicator such as ROE to consider as of most importance; however, we recognize that as a listed company, we should continue to grow to meet expectation by our shareholders.
We understand that our business model; that is, worldwide sale of automated DNA extraction instruments through our OEM partners has been successful. As the current business model will not change for the time being and will concentrate on improving product competitiveness in both performance and cost.
At the same time, PSS continue to elaborate on developing automated detection system of genes and proteins for diagnostic use. In the middle to long period, we aim to grow to the company that supplies infrastructures to bio-industry.
To achieve our goal, we might need the various measures including strengthening of our R&D capability, closer collaboration with reagent and apparatus manufacturers in bio-industry or acquisition of them.